Sarah Pett
#179,585
Most Influential Person Now
British immunopathologist and COVID-19 researcher
Sarah Pett's AcademicInfluence.com Rankings
Sarah Pettbiology Degrees
Biology
#15560
World Rank
#19569
Historical Rank
Pathology
#240
World Rank
#402
Historical Rank
Immunology
#1073
World Rank
#1099
Historical Rank
Download Badge
Biology
Sarah Pett's Degrees
- PhD Immunology University of Oxford
Why Is Sarah Pett Influential?
(Suggest an Edit or Addition)According to Wikipedia, Sarah L. Pett is a Professor of Infectious Diseases at University College London. Pett is interested in the immunopathology of infections and the development of optimised treatment pathways for infections. During the COVID-19 pandemic, Pett led a clinical trial that investigated the efficacy of remdesivir as a treatment for coronavirus disease.
Sarah Pett's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Remdesivir for the Treatment of Covid-19 — Final Report (2020) (4464)
- Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study (2020) (908)
- Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. (2010) (790)
- The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory (1993) (358)
- High Levels of Human Antigen-Specific CD4+ T Cells in Peripheral Blood Revealed by Stimulated Coexpression of CD25 and CD134 (OX40)1 (2009) (146)
- British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2015 (2016) (140)
- Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa (2017) (136)
- Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over‐active CD4+ T‐cell responses in HIV‐positive patients with mycobacterial immune restoration disease (2009) (135)
- Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study (2013) (124)
- Factors Associated With Plasma IL-6 Levels During HIV Infection. (2015) (121)
- Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. (2005) (113)
- Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial (2021) (103)
- UK-Wide Surveillance of Neurological and Neuropsychiatric Complications of COVID-19: The First 153 Patients (2020) (103)
- Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial (2019) (83)
- Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial (2019) (83)
- Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study (2021) (81)
- Chagas disease in Australia and New Zealand: risks and needs for public health interventions (2014) (74)
- THE ROLE OF APOPTOSIS IN T-CELL MEMORY (1993) (69)
- Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial (2020) (64)
- Post-Kala-Azar Dermal Leishmaniasis Due to Leishmania infantum in a Human Immunodeficiency Virus Type 1-Infected Patient (2006) (58)
- The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection: Results of Two International Observational Cohort Studies (2013) (57)
- Defining causality in COVID-19 and neurological disorders (2020) (55)
- Human antigen‐specific CD4+CD25+CD134+CD39+ T cells are enriched for regulatory T cells and comprise a substantial proportion of recall responses (2014) (51)
- Skeletal Muscle Toxicity Associated With Raltegravir-Based Combination Antiretroviral Therapy in HIV-Infected Adults (2013) (41)
- No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV. (2020) (36)
- Performance of the inFLUenza Patient-Reported Outcome (FLU-PRO) diary in patients with influenza-like illness (ILI) (2018) (34)
- Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder (2021) (32)
- Non-starch polysaccharide intake of a representative sample of British adults. (1990) (31)
- Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization (2017) (29)
- Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial (2022) (29)
- Antibody-dependent effector functions against HIV decline in subjects receiving antiretroviral therapy. (2015) (28)
- Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial (2018) (27)
- Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial (2022) (27)
- Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial (2018) (27)
- Immunomodulators as adjunctive therapy for HIV-1 infection. (2001) (26)
- Role of Interleukin-2 in Patients with HIV Infection (2012) (26)
- Cytokine therapies in HIV-1 infection: present and future (2003) (25)
- Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial (2018) (24)
- Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH S (2016) (23)
- Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial (2018) (23)
- Reliability, Validity, and Responsiveness of InFLUenza Patient-Reported Outcome (FLU-PRO©) Scores in Influenza-Positive Patients. (2017) (23)
- A novel assay detecting recall response to Mycobacterium tuberculosis: Comparison with existing assays. (2012) (23)
- Reporting and Evaluation of HIV-Related Clinical Endpoints in Two Multicenter International Clinical Trials (2006) (22)
- Biomarkers and Bacterial Pneumonia Risk in Patients with Treated HIV Infection: A Case-Control Study (2013) (22)
- Clinical studies with chemokine receptor-5 (CCR5)-inhibitors (2012) (21)
- Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial (2018) (21)
- Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial (2018) (21)
- Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study (2018) (21)
- Anal cytological abnormalities are poor predictors of high-grade intraepithelial neoplasia amongst HIV-positive men who have sex with men. (2013) (21)
- A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated Adults (2012) (20)
- Substantial Improvements in Performance Indicators Achieved in a Peripheral Blood Mononuclear Cell Cryopreservation Quality Assurance Program Using Single Donor Samples (2006) (20)
- Restoration of CMV-Specific-CD4 T Cells with ART Occurs Early and Is Greater in Those with More Advanced Immunodeficiency (2013) (18)
- The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis (2021) (18)
- Immunotherapies in HIV-1 infection (2009) (18)
- Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance study (2021) (16)
- Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study (2019) (16)
- Association of Suboptimal Antiretroviral Therapy Adherence With Inflammation in Virologically Suppressed Individuals Enrolled in the SMART Study (2017) (15)
- Incomplete restoration of Mycobacterium tuberculosis-specific-CD4 T cell responses despite antiretroviral therapy. (2014) (15)
- Enhanced infection prophylaxis reduces mortality in severely immunosuppressed HIV-infected adults and older children initiating antiretroviral therapy in Kenya, Malawi, Uganda and Zimbabwe: the REALITY trial (2016) (14)
- A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection. (2010) (14)
- Identifying Chagas disease in Australia: an emerging challenge for general practitioners. (2014) (14)
- A randomised controlled trial comparing the impact of antiretroviral therapy (ART) with a "Kick-and-Kill" approach to ART alone on HIV reservoirs in individuals with primary HIV infection (PHI); RIVER trial (2018) (14)
- Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009–2015 (2017) (13)
- Results of External Quality Assessment for Proviral DNA Testing of HIV Tropism in the Maraviroc Switch Collaborative Study (2013) (12)
- Assessment of arterial elasticity among HIV‐positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial (2015) (11)
- Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study (2017) (11)
- Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study (2017) (11)
- Determinants of IL-6 levels during HIV infection (2014) (10)
- Participants' perspectives of self-collected anal cytological swabs. (2011) (10)
- A Phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients (2009) (9)
- A Phase I Study of the Pharmacokinetics and Safety of Passive Immunotherapy with Caprine Anti-HIV Antibodies, PEHRG214, in HIV-1--Infected Individuals (2004) (9)
- Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3) (2020) (9)
- The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19 (2022) (9)
- Ratios of effector to central memory antigen‐specific CD4+ T cells vary with antigen exposure in HIV+ patients (2014) (9)
- Enfuvirtide injection site reactions: A clinical and histopathological appraisal (2011) (8)
- Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic (2018) (7)
- Genetic Variants of APOL1 Are Major Determinants of Kidney Failure in People of African Ancestry With HIV (2022) (7)
- Disability and Modern Fiction: Faulkner, Morrison, Coetzee, and the Nobel Prize for Literature (2013) (7)
- Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic (2018) (7)
- Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. (2020) (7)
- Anti-Influenza Hyperimmune Immunoglobulin Enhances Fc-Functional Antibody Immunity During Human Influenza Infection (2018) (7)
- Metabolite profiles associated with disease progression in influenza infection (2021) (7)
- Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3) (2021) (6)
- Design and implementation of the multi-arm, multi-stage Therapeutics for Inpatients with COVID-19 (TICO) platform master protocol: An Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative (2020) (6)
- Antigen dose and keratinocyte antigen presentation are specific determinants of T cell function in atopic eczema (2011) (6)
- Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery (2022) (6)
- Characterising neuropsychiatric disorders in patients with COVID-19 – Authors' reply (2020) (6)
- HIV fusion inhibitors: A review (2008) (6)
- Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. (2021) (5)
- Participants' perspectives of high resolution anoscopy. (2011) (5)
- Cyclical hepatitis and early liver cirrhosis after hepatitis C seroconversion during pulsed antiretroviral therapy for primary HIV-1. (2002) (5)
- High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study (2021) (4)
- The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam (2019) (3)
- Rash Reading: Rethinking Virginia Woolf's On Being Ill (2019) (3)
- Sickle Cell Trait and Kidney Disease in People of African Ancestry With HIV (2021) (3)
- The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam (2019) (3)
- Evaluation of the Performance Properties of the Influenza Patient-Reported Outcomes Instrument (Flu-Pro) (2016) (3)
- Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C (2021) (3)
- J.M. Coetzee and the power of narrative (2012) (3)
- Current review of the metabolic and endocrine disturbances in human immunodeficiency virus infection (2000) (2)
- Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings (2020) (2)
- Impact of Dexamethasone and Remdesivir on Neurological Complications during COVID-19 (2022) (2)
- Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. (2020) (2)
- 12-week raltegravir-intensified quadruple therapy versus triple first-line ART reduces viral load more rapidly but does not reduce mortality in severely immunosuppressed African HIV-infected adults and older children: the REALITY trial (2016) (2)
- SARS-CoV-2 immunity and vaccine strategies in people with HIV (2022) (2)
- No overall impact on rate of weight gain with integrase inhibitor‐containing regimens in antiretroviral‐naïve adults (2021) (2)
- Defining Causality in Neurological & Neuropsychiatric COVID-19 Vaccine Complications: What Have We Learnt from Current and Previous Vaccination Campaigns? (2021) (2)
- Labour pains: eliminating HCV in women and children. (2021) (2)
- Prevalence of HIV/hepatitis B and HIV/hepatitis C coinfection among people of East, South, Central and West African ancestry in the United Kingdom. (2021) (2)
- (Re)writing the black feminist text: (2007) (1)
- Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study (2022) (1)
- Performance of human papillomavirus DNA detection in residual specimens taken for Chlamydia trachomatis and Neisseria gonorrhoeae nucleic acid amplification testing in men who have sex with men (2020) (1)
- GSTM1 Copy Number and Kidney Disease in People With HIV (2022) (1)
- Antiretroviral therapy-induced immune restoration in HIV infection: a double-edged sword? (2004) (1)
- AIDS as a World Health Problem (2003) (1)
- Fewer COVID‐19 Neurological Complications with Dexamethasone and Remdesivir (2022) (1)
- Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 (2022) (1)
- Evaluating the reactivation of herpesviruses and inflammation as cardiovascular and cerebrovascular risk factors in antiretroviral therapy initiators in an African HIV-infected population (RHICCA): a protocol for a longitudinal cohort study (2019) (1)
- Prevention of Neurological Complications During COVID-19: Protocol for a Retrospective Analysis of the ISARIC4C National Cohort (2022) (1)
- A Randomized Comparison of Antiretroviral Therapy Alone Versus Antiretroviral Therapy with a 'Kick-and-Kill' Approach, on Measures of the HIV Reservoir Amongst Participants with Recent HIV Infection: The RIVER Trial (2019) (1)
- HIV-1 protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor with two nucleoside analogue HIV-1 reverse transcriptase inhibitors (0)
- AIDS: Understanding HIV Transmission (2003) (0)
- Ready-to-Use Supplementary Food to Prevent Mortality in Severely Immunocompromised Individuals Initiating Antiretroviral Therapy in Africa: An Open-label Randomised Controlled Trial (2018) (0)
- Stimulated Coexpression of CD 25 and T Cells in Peripheral Blood Revealed by + High Levels of Human Antigen-Specific CD 4 (2009) (0)
- Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine. (2023) (0)
- Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa (2017) (0)
- Review of: Accented Futures: Language Activism and the Ending of Apartheid by Carli Coetzee. Wits University Press, 2013. (2015) (0)
- Accented Futures: language activism and the ending of apartheid by Carli Coetzee (review) (2016) (0)
- Changes in CCR5+ cells and antigen-specific CD4+ T-cells during monotherapy with a CCR5 antagonist SCH532706 compared with combination therapy (2008) (0)
- Postcolonial Text 9.4. Special Issue: The Parapostcolonial: Interdisciplinary Perspectives and New Approaches (2014) (0)
- Reviews (2011) (0)
- Managing two decades of visceral leishmaniasis and HIV co-infection: a case report that illustrates the urgent research needs in the field. (2017) (0)
- A difficult equilibrium: torture narratives and the ethics of reciprocity in apartheid South Africa and its aftermath (2009) (0)
- Clearance of HPV Anal Premalignant Lesions and Modulation of Systemic Immune Responses to HPV Oncogenes with Low Dose Pomalidomide (2019) (0)
- Adaptive COVID-19 treatment trial in the EU & UK (2020) (0)
- Cultured violence: narrative, social suffering, and engendering human rights in contemporary South Africa (2011) (0)
- Spectrum, risk factors and outcomes of neurological complications of COVID-19 (2021) (0)
- Reply to “Issues on Results of the External Quality Assessment for Proviral DNA Testing of HIV-1 Tropism in the Maraviroc Switch Collaborative Study” (2013) (0)
- Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses. (2021) (0)
- Antiretroviral agents: Focus on Maraviroc for the Treatment of HIV-1-Infected Adults (2010) (0)
- The Parapostcolonial: Interdisciplinary Perspectives and New Approaches (2015) (0)
- International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
- Breather Plus: Short-cycle HIV therapy (5 days on/2 days off) in young people (12-19 years) with chronic HIV infection in sub-Saharan Africa (2020) (0)
- Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status. (2020) (0)
- Increased Kynurenine: tryptophan Ratio As A Marker Of Enhanced Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome In Adults Hospitalised With Influenza Enrolled In The Insight Flu003plus Study (2017) (0)
- Prevention of neurological complications during COVID-19: a retrospective analysis of the ISARIC4C national cohort (2022) (0)
- CARLI COETZEE , Accented Futures: language activism and the ending of apartheid . Johannesburg: Wits University Press (pb $34.95 – 978 1 86814 740 3). 2013, xvi + 182 pp. (2016) (0)
- Factors associated with IL-6 levels during HIV infection (2014) (0)
- Proviral DNA testing of HIV tropism in the Maraviroc Switch Collaborative Study (MARCH) - results of a three-phase quality assurance (QA) programme (2013) (0)
- Editorial (2000) (0)
- Neurological and Psychiatric Manifestations of COVID-19 in UK Children: A Prospective National Cohort Study (2021) (0)
- Genotype 4 and the global challenge of hepatitis C treatment. (2016) (0)
- No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach (2021) (0)
- Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT (2021) (0)
- Causes and timing of mortality and morbidity among late presenters starting ART in the REALITY trial (2018) (0)
- Substantial improvements in performance indicators achieved in a PBMC cryopreservation quality assurance program using single donor samples. (2006) (0)
- Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus (2023) (0)
- Acceptability of HCV screening and potential use of DAAs during pregnancy in women attending antenatal care in Egypt, Pakistan and Ukraine (2021) (0)
- P499 Human papillomavirus detection in residual samples from STI tests in men who have sex with men (2019) (0)
- STRATEGIC TREATMENT OPTIMIZATION FOR HCV (STOPHCV-1): AN OPEN-LABEL RANDOMIZED CONTROLLED TRIAL OF SHORT DURATION THERAPY FOR CHRONIC HEPATITIS C (2019) (0)
- Reading and Writing Chronic Illness, 1990-2012: Ethics and Aesthetics at Work (2014) (0)
- Maraviroc Switch Collaborative Study Proviral DNA Testing of HIV Tropism in the Results of External Quality Assessment for (2013) (0)
- Quality of cause-of-death reporting in an on-going UK cohort study; 1996-2012 (2016) (0)
This paper list is powered by the following services:
Other Resources About Sarah Pett
What Schools Are Affiliated With Sarah Pett?
Sarah Pett is affiliated with the following schools:
